These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

526 related articles for article (PubMed ID: 30138325)

  • 21. Chemotherapy and novel targeted therapies for operable esophageal and gastroesophageal junctional cancer.
    van den Ende T; Smyth E; Hulshof MCCM; van Laarhoven HWM
    Best Pract Res Clin Gastroenterol; 2018; 36-37():45-52. PubMed ID: 30551856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of 5-flurouracil-based neoadjuvant chemotherapy in locally-advanced gastric/gastroesophageal cancer: a meta-analysis.
    Ge L; Wang HJ; Yin D; Lei C; Zhu JF; Cai XH; Zhang GQ
    World J Gastroenterol; 2012 Dec; 18(48):7384-93. PubMed ID: 23326149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant Chemoradiotherapy Improving Survival Outcomes for Esophageal Carcinoma: An Updated Meta-analysis.
    Wang DB; Sun ZY; Deng LM; Zhu DQ; Xia HG; Zhu PZ
    Chin Med J (Engl); 2016 Dec; 129(24):2974-2982. PubMed ID: 27958230
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for esophageal cancer: a meta-analysis.
    Jing SW; Qin JJ; Liu Q; Zhai C; Wu YJ; Cheng YJ; Czito BG; Wang J
    Future Oncol; 2019 Jul; 15(20):2413-2422. PubMed ID: 31269806
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy of the prophylactic use of octreotide for the prevention of complications after pancreatic resection: An updated systematic review and meta-analysis of randomized controlled trials.
    Wang C; Zhao X; You S
    Medicine (Baltimore); 2017 Jul; 96(29):e7500. PubMed ID: 28723761
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis.
    Qin H; Liu F; Zhang Y; Liang Y; Mi Y; Yu F; Xu H; Li K; Lin C; Li L; Tian Z; Wang L
    Front Immunol; 2023; 14():1108213. PubMed ID: 37033991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction - a prospective cohort pilot study within a randomized clinical trial.
    Lund M; Alexandersson von Döbeln G; Nilsson M; Winter R; Lundell L; Tsai JA; Kalman S
    Radiat Oncol; 2015 Jan; 10():16. PubMed ID: 25582305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data.
    Ronellenfitsch U; Schwarzbach M; Hofheinz R; Kienle P; Kieser M; Slanger TE; Burmeister B; Kelsen D; Niedzwiecki D; Schuhmacher C; Urba S; van de Velde C; Walsh TN; Ychou M; Jensen K
    Eur J Cancer; 2013 Oct; 49(15):3149-58. PubMed ID: 23800671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant immunotherapy improves outcomes for resectable gastroesophageal junction cancer: A systematic review and meta-analysis.
    Wu D; Yang L; Yan Y; Jiang Z; Liu Y; Dong P; Lv Y; Zhou S; Qiu Y; Yu X
    Cancer Med; 2024 May; 13(9):e7176. PubMed ID: 38716645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surgical Outcomes in Total Neoadjuvant Therapy for Rectal Cancer Versus Standard Long-course Chemoradiation: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Lin W; Li C; Clement EA; Brown CJ; Raval MJ; Karimuddin AA; Ghuman A; Phang PT
    Ann Surg; 2024 Apr; 279(4):620-630. PubMed ID: 38009646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.
    Gebski V; Burmeister B; Smithers BM; Foo K; Zalcberg J; Simes J;
    Lancet Oncol; 2007 Mar; 8(3):226-34. PubMed ID: 17329193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
    Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
    Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is Total Neoadjuvant Treatment Beneficial for Locally Advanced Rectal Cancer? A Meta-Analysis of Randomized Controlled Trials.
    Wu HQ; Li J; Miao JD; Li JW
    Oncology; 2024; 102(5):399-413. PubMed ID: 37926087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prolonged interval between neoadjuvant chemoradiotherapy and esophagectomy does not benefit the outcome in esophageal cancer: a systematic review and meta-analysis.
    Tie H; He F; Shen J; Zhang B; Ye M; Chen B; Wu Q
    Dis Esophagus; 2018 Jan; 31(1):1-9. PubMed ID: 29087451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy and safety of total neoadjuvant therapy versus neoadjuvant chemoradiotherapy in the treatment of locally advanced rectal cancer: a meta-analysis].
    Zhang YQ; Sun KG; Lu JY; Ma J; Yao N; Qin ZH; Yao YH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jun; 25(6):531-538. PubMed ID: 35754218
    [No Abstract]   [Full Text] [Related]  

  • 36. Association between time interval from neoadjuvant chemoradiotherapy to surgery and complete histological tumor response in esophageal and gastroesophageal junction cancer: a national cohort study.
    Klevebro F; Nilsson K; Lindblad M; Ekman S; Johansson J; Lundell L; Ndegwa N; Hedberg J; Nilsson M
    Dis Esophagus; 2020 May; 33(5):. PubMed ID: 31676895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant chemoradiotherapy could improve survival outcomes for esophageal carcinoma: a meta-analysis.
    Wang DB; Zhang X; Han HL; Xu YJ; Sun DQ; Shi ZL
    Dig Dis Sci; 2012 Dec; 57(12):3226-33. PubMed ID: 22695886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome of neoadjuvant therapies for cancer of the oesophagus or gastro-oesophageal junction based on a national data registry.
    Klevebro F; Lindblad M; Johansson J; Lundell L; Nilsson M
    Br J Surg; 2016 Dec; 103(13):1864-1873. PubMed ID: 27689845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: a meta-analysis.
    Jin HL; Zhu H; Ling TS; Zhang HJ; Shi RH
    World J Gastroenterol; 2009 Dec; 15(47):5983-91. PubMed ID: 20014464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.
    Sjoquist KM; Burmeister BH; Smithers BM; Zalcberg JR; Simes RJ; Barbour A; Gebski V;
    Lancet Oncol; 2011 Jul; 12(7):681-92. PubMed ID: 21684205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.